CoreWeave vs Enveric Biosciences Inc — how do they compare? CoreWeave trades at $83.82 (market cap $48.78B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: CoreWeave is far larger — about 7291.5× Enveric Biosciences Inc's market cap, and CoreWeave is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold CoreWeave for 6 Days and Enveric Biosciences Inc for 14 Days on average.
| CRWV | ENVB | |
|---|---|---|
Market Cap | $48.78B | $6.69M |
Volume | 19,704,178 | 41,141 |
Sector | Technology | Health |
52-Week High | $143.08 | $10.80 |
52-Week Low | $60.82 | $1.27 |
Typical Hold Time | 6 Days | 14 Days |
Enterprise Value | $94.85B | -$1.60M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CoreWeave provides cloud computing infrastructure designed for AI workloads. Its platform gives organizations access to large-scale GPU computing and cloud services for training and running AI models.
Read more on CRWV →Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →